title: Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples.
abstract: The molecular mechanisms underlying the development of bone metastases in breast cancer remain unclear. Disseminated tumour cells (DTCs) in the bone marrow of breast cancer patients are commonly identified, even in early stage disease, but their potential to initiate metastases is not known. The mechanism whereby DTCs become overt metastatic tumour cells (MTCs) is therefore, an area of considerable interest. This study explored the analysable yield of genetic material from human biopsy samples in order to describe differences in gene expression between DTCs and bone MTCs. Thirteen breast cancer patients with bone metastases underwent a CT-guided bone metastasis biopsy and a bone marrow biopsy. Tumour cells were enriched and gene expression profiling was conducted to identify differentially expressed genes. The analysable yield of sufficient RNA for microarray analysis was 60% from bone metastasis biopsies and 80% from bone marrow biopsies. A signature of 133 candidate genes differentially expressed between DTCs and MTCs was identified. Several genes relevant to breast cancer metastasis to bone (osteopontin, CTGF, parathyroid hormone receptor, EGFR) were significantly overexpressed in MTCs as compared to DTCs. Biopsies of bone metastases and bone marrow rarely yield enough tissue for robust molecular biology studies using clinical samples. The findings obtained however are interesting and seem to overlap with the bone metastasis gene expression signature described in murine xenograft models. Larger biopsy specimens or improved RNA extraction techniques may improve analysable yield and feasibility of these techniques.
authors.affiliation: Division of Applied Molecular Oncology, Princess Margaret Hospital, Toronto, ON, Canada.
authors.forename: T R
authors.initials: TR
authors.lastname: Cawthorn
authors.forename: E
authors.initials: E
authors.lastname: Amir
authors.forename: R
authors.initials: R
authors.lastname: Broom
authors.forename: O
authors.initials: O
authors.lastname: Freedman
authors.forename: D
authors.initials: D
authors.lastname: Gianfelice
authors.forename: D
authors.initials: D
authors.lastname: Barth
authors.forename: D
authors.initials: D
authors.lastname: Wang
authors.forename: I
authors.initials: I
authors.lastname: Holen
authors.forename: S J
authors.initials: SJ
authors.lastname: Done
authors.forename: M
authors.initials: M
authors.lastname: Clemons
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000378:metabolism; D001706:Biopsy; D001853:Bone Marrow / Q000473:pathology; D001859:Bone Neoplasms / Q000235:genetics* / Q000556:secondary*; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology*; D005240:Feasibility Studies; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000473:pathology; D009360:Neoplastic Cells, Circulating; D011446:Prospective Studies; D012334:RNA, Neoplasm / Q000032:analysis
chemical_list: D014408:Biomarkers, Tumor; D012334:RNA, Neoplasm
references.citation: N Engl J Med. 2004 Dec 30;351(27):2817-26
references.pmid: 15591335
references.citation: J Clin Oncol. 1998 Jun;16(6):2038-44
references.pmid: 9626201
references.citation: N Engl J Med. 2009 Jan 1;360(1):53-62
references.pmid: 19118304
references.citation: Clin Oncol (R Coll Radiol). 2008 Dec;20(10):763-8
references.pmid: 18824337
references.citation: Cancer. 2000 Mar 1;88(5):1082-90
references.pmid: 10699899
references.citation: Ann Surg Oncol. 2007 Jun;14(6):1896-903
references.pmid: 17356955
references.citation: Cancer. 2001 Jul 1;92(1):46-53
references.pmid: 11443608
references.citation: J Biol Chem. 2007 Sep 14;282(37):26656-26665
references.pmid: 17636266
references.citation: J Clin Oncol. 1999 Mar;17(3):846-54
references.pmid: 10071275
references.citation: Oncologist. 2001;6(2):125-32
references.pmid: 11306724
references.citation: Cancer Cell. 2003 Jun;3(6):537-49
references.pmid: 12842083
references.citation: J Immunol Methods. 2005 May;300(1-2):136-45
references.pmid: 15907331
references.citation: Biochim Biophys Acta. 2009 Aug;1796(1):27-32
references.pmid: 19406208
references.citation: Bioinformatics. 2003 Jan 22;19(2):185-93
references.pmid: 12538238
references.citation: Breast Cancer Res. 2006;8(2):R13
references.pmid: 16542503
references.citation: Nat Biotechnol. 2006 Sep;24(9):1151-61
references.pmid: 16964229
references.citation: Anticancer Res. 1999 Jul-Aug;19(4C):3383-92
references.pmid: 10629624
references.citation: J Clin Oncol. 1996 Sep;14(9):2552-9
references.pmid: 8823335
references.citation: Clin Cancer Res. 2005 May 15;11(10):3678-85
references.pmid: 15897564
references.citation: J Clin Oncol. 2005 May 20;23(15):3314-21
references.pmid: 15738536
references.citation: Cancer Res. 2005 Jun 15;65(12):4993-7
references.pmid: 15958538
references.citation: Diagn Pathol. 2009 Mar 24;4:9
references.pmid: 19317905
references.citation: Nature. 2002 Jan 31;415(6871):530-6
references.pmid: 11823860
references.citation: N Engl J Med. 2005 Aug 25;353(8):793-802
references.pmid: 16120859
references.citation: Ann Oncol. 2009 Sep;20(9):1499-1504
references.pmid: 19299408
references.citation: Cancer Res. 2006 Mar 15;66(6):2918-22
references.pmid: 16540638
references.citation: Ann Oncol. 2008 Dec;19(12):2007-11
references.pmid: 18664560
references.citation: N Engl J Med. 2009 Feb 12;360(7):679-91
references.pmid: 19213681
references.citation: Am J Pathol. 1999 Jan;154(1):61-6
references.pmid: 9916919
references.citation: Cancer. 1997 Oct 15;80(8 Suppl):1588-94
references.pmid: 9362426
references.citation: Cancer. 2004 Aug 15;101(4):693-703
references.pmid: 15305398
references.citation: Clin Cancer Res. 2004 Feb 15;10(4):1392-400
references.pmid: 14977842
references.citation: Breast Cancer Res. 2008;10 Suppl 1:S1
references.pmid: 19091005